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Inflammation and insulin resistance are characteristics of endotoxemia.  While the role of 
interleukin-6 (IL-6) in insulin resistant states has been characterized, little is known of its 
role in the metabolic response to inflammation.  To study the role of IL-6, conscious 
chronically catheterized mice were used.  Five days prior to being studied, catheters were 
implanted in the carotid artery and jugular vein.  After a 5 h fast, E.coli (250 µg/mouse) 
LPS was injected in IL6-/- (KO; n=13), IL6+/- (HET; n=9), and IL-6+/+ (WT; n=10) 
littermates.  The IL-6 response to LPS was simulated in an additional group of KO mice 
(KO+IL6; n=10).  Glucose turnover (Ra) was assessed using 3-[3H]-D-glucose.  IL-6 
increased similarly in WT and HET (15±0.7 and 14±0.5 ng/ml) 4h after LPS and was 
undetectable in KO.  IL-6 replacement in KO restored circulating IL-6 to levels observed 
in the WT group (14±0.3 ng/ml).  WT was the only group to experience an early rise in 
tumor necrosis factor-α (TNF-α).  Interleukin-1β (IL-1β) was similar in all groups.  KO 
exhibited a more profound hyperglycemia 30 min after LPS injection and no apparent 
hypoglycemia at 4h (95±5 mg/dl).  Glucose levels in KO+IL6, while decreased (93±4 
mg/dl) at 4h, remained higher than WT.  Ra was not altered.  In summary, the absence of 
IL-6 protected against LPS induced hypoglycemia.  Acute restoration of the IL-6 
response to LPS did not potentiate hypoglycemia.  Thus, while IL-6 promotes glucose 
intolerance in insulin resistant states, IL-6 promotes hypoglycemia during inflammation. 
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CHAPTER I 
 
INTRODUCTION 
 
 The pathogenic effects of gram-negative bacteria are primarily brought about by 
exposure within the mammalian host to the bacterial endotoxic component called 
lipopolysaccharide (LPS).  Exposure to LPS results in a subsequent chain of events that 
varies widely but can consist of infection, the systemic inflammatory response syndrome 
(SIRS) plus infection, septic shock, multiple organ dysfunction syndrome (MODS) and 
eventually death (93).  Sepsis, or endotoxemia, has been described as “an infection-
induced syndrome defined as the presence of two or more of the following features of 
systemic inflammation: fever or hypothermia, leukocytosis or leucopenia, tachycardia, 
and tachypnea or a supranormal minute ventilation” (13).  Severe sepsis is defined as 
sepsis accompanied by acute organ dysfunction (64).  Epidemiological analysis yields 
estimates of roughly 750,000 cases of severe sepsis occur in the United States per year 
(3).  Crude mortality rates resulting from severe sepsis range from 28% to 50% and are 
considered unacceptably high (3).   
There are multiple hurdles involved in the adequate treatment of hospitalized 
patients with septicemia; the most profound is the difficulty in choosing a proper 
therapeutic regimen.  This arises because of the complicated nature of evaluating 
investigational agents in patients with severe sepsis (64).  There are multiple reasons for 
this problem, to include: 
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 the heterogeneity of the syndrome and patient population  
 lack of translated success from animal model to human 
 patients present with more complicated than simple endotoxin challenge 
 the immunopathogenesis is a complex and dynamic process 
 coagulation issues 
 multiple influences on the outcome in severe sepsis 
 clinical definitions of SIRS, sepsis and severe sepsis are not sufficiently precise 
 a failure to adequately power sepsis trials  
(64).  
 
For these reasons, there has historically been little success in the development of an 
adequate broad-spectrum treatment for severe septicemia.  Treatments thus far have 
consisted of antimicrobial drugs, cytokine antagonists (96), intensive insulin therapy 
(86,87) and administration of recombinant human activated protein C (10), with cytokine 
antagonists alone being the least successful (96).  Antimicrobial drugs are necessary but 
not sufficient for the treatment of sepsis.  Ironically, antimicrobial drugs may actually 
precipitate septic changes by liberating antimicrobial products (62).   
Sepsis profoundly alters systemic hemodynamics and metabolism.  Early sepsis is 
characterized by a hypermetabolic phase consisting of a pattern of increased cardiac 
output, decreased systemic vascular resistance, and a redistribution of organ blood flow.  
These responses are associated with elevations of circulating insulin and 
counterregulatory hormones and the release of inflammatory mediators (18).  Intensive 
insulin therapy has been shown to be promising in that the incidence of bacteremia and 
sepsis is significantly reduced with the utilization of insulin (87).  More recent studies 
involving intensive insulin therapy would indicate the beneficial effects seen with an 
insulin regimen might be more a function of control of hyperglycemia than direct effects 
of the insulin itself (86).   
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Regardless, recombinant human activated protein C is the only current treatment 
for sepsis recognized by the Food and Drug Administration.  Recombinant human 
activated protein C has the benefit of providing anti-inflammatory, antithromobotic and 
profibrinolytic properties.  All of these properties prove to be essential in efficient 
recovery from an endotoxic insult. 
 
The Metabolic Response to Endotoxin 
Initially, patients with septicemia experience an increase in the mobilization and 
utilization of glucose in conjunction with a major influx of immunologic factors.  One 
important feature of the hypermetabolic response in vivo is an increase in the synthesis 
and release of glucose from the liver early in an endotoxin challenge (46).  This leads to a 
brief state of hyperglycemia coupled with elevated insulin levels (20,54,95).  This 
increase in glucose appears to be unaffected by the elevation in insulin secretion.  A state 
of insulin resistance develops in the presence of conditions favorable for 
gluconeogenesis.  These conditions are characterized by lactic acidemia, increased 
plasma amino acids and increased levels of glucogenic hormones (18,22,36).  The 
resistance to the effects of insulin is likely a result of not only the sustained high output 
of glucose by the liver but also in decreased insulin-stimulated utilization of glucose by 
muscle and other peripheral tissues (20). 
Endotoxemia can be divided into two categories with two different series of 
metabolic outcomes.  The first category, low dose endotoxemia, is more experimental in 
nature and has less clinical relevance.  Low dose endotoxemia is considered important, as 
it is a means to study the metabolic intermediates between the states of health and high 
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dose endotoxemia.  This condition displays a transient hyperglycemia that is a result of 
the increased rate of glucose production that exceeds the enhanced glucose utilization by 
peripheral tissues (45).  The circulating glucose level gradually returns to basal values 
without ever falling to a hypoglycemic level.  It is thought that the elevated circulating 
levels of catabolic hormones and increased gluconeogenic precursor availability are 
responsible for the maintenance of hepatic glucose production and supply of glucose to 
sustain the increased demands of peripheral tissues (45). 
The second category, high dose endotoxemia, is more clinically relevant and is 
often recapitulated in animal models as a means to better understand the metabolic and 
immunologic complexity of this condition.  Like low dose endotoxemia, this condition 
displays a transient hyperglycemia early in infection, although it can produce a severe 
hypoglycemia that appears to result primarily from a subsequent reduction in hepatic 
glucose production (44).  This results from the depletion of hepatic glycogen reserves and 
later impairment in the gluconeogenic capacity and hormonal responsiveness in the liver 
(44).  Throughout a four-hour period, rates of glucose production, glucose recycling, and 
glucose clearance become elevated and typically remain elevated long after early 
hyperglycemia (78).  Studies conducted in rats by Lang et al. (44) and Buday et al. (16) 
have shown that when given a bolus of LPS, rats had a dramatic increase in early glucose 
concentration and, by the end of the study, had an increase in all other parameters 
measured with the exception of insulin, hepatic glycogen and muscle glycogen (Table 1). 
 
 
4 
Table 1:  Metabolic and Hormonal Alterations Induced by E. coli Endotoxin. 
 
Analyte 
% change 
over basal 
  
Metabolic Parameter 
% change 
over basal 
Glucose at 1 h 
Glucose at 4 h 
Lactate at 4 h 
Insulin at 4 h 
Glucagon at 4 h 
Norepinephrine at 4 h 
Epinephrine at 1 h 
Epinephrine at 4 h 
Corticosterone at 4 h 
+69% 
 
+19% 
 
+86% 
 
-29% 
 
+340% 
 
+750% 
 
+3300% 
 
+2500% 
 
+300% 
 Ra at 1 h 
 
Ra at 4 h 
 
Glucose Recycling at 4 h 
 
Glucose Clearance at 4 h 
 
Liver Glycogen* at 4 h 
 
Muscle Glycogen* 4 h 
+70% 
 
+28% 
 
+290% 
 
+17% 
 
-86% 
 
-27% 
 
g
i
a
i
o
i
i
(
eTable adapted from data collected by Lang et al. (44) and Buday et al. (16).  Glycogen data (*) has 
been obtained from Buday et al., all other data is from Lang et al..  Ra is endogenous glucose 
production. The increased rate of production represents primarily the early increased rate of 
luconeogenesis.  Although there is a relatively prolonged increase in glucose production 
n the early phase of endotoxemia, this increase is not sustained but instead is followed by 
 hypoglycemic phase characterized by a depression in gluconeogenesis (47).  The 
ncreased rate of glucose carbon recycling indicates an accelerated peripheral conversion 
f glucose to lactate, and subsequent conversion to glucose via hepatic gluconeogenesis 
s driven in part by the rising arterial lactate concentration (78).  Gluconeogenesis is 
ncreased in vivo in spite of a decrease in the gluconeogenic rate-limiting enzyme PEPCK 
47).  Previous studies suggest that the elevated gluconeogenesis observed during the 
arly hyperglycemic phase is associated with increases in both glucose-6-phosphatase 
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mRNA levels and enzymatic activity (48) whereas glucose-6-phosphatase activity is 
decreased during the hypoglycemic phase of endotoxemia (6).   
It has been observed that primary gluconeogenic enzymes such as 
phosphoenolpyruvate carboxykinase (PEPCK) (25), glucose-6-phosphatase and fructose-
1,6-diphosphatase (53) are greatly reduced  during infection.  Fructose-2,6-biphosphate is 
the most potent regulator of gluconeogenesis and is rapidly accumulated early in 
infection.  The outcome is the eventual stimulation of phosphofructo-kinase activity 
leading to the preferential shunting of hexoses through the glycolysis pathway rather than 
toward the gluconeogenic pathway later in infection (5).  The resulting consequence can 
be hypoglycemia as a result of a depleted glucose reserves.  Conversely, it has been 
observed that rates of gluconeogenesis are greatly depressed in isolated perfused livers 
obtained from septic rats when substrate delivery and hormonal stimulation are 
standardized to sham livers (21).  Studies using lactate as a substrate for gluconeogenesis 
showed lactate dependent increases in glucose production declined by 50% in perfused 
livers obtained from septic rats (21).  The actual mechanism by which endotoxin 
interferes with gluconeogenesis is still unknown.  The differences in gluconeogenesis 
observed in septic in vivo and ex vivo liver studies may be attributed to differences in 
liver damage caused by endotoxic insult.  Although variations between models are 
apparent, the isolated perfused liver model has an important role in studying the primary 
effects of endotoxemia, as this model is void of the interference of the cardiovascular 
system, the nervous system, the adrenal glands, and other tissues.  Regardless, the in vivo 
system remains our model of choice due to the functioning completeness of the whole 
body system.   
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 The muscle response to endotoxin has been studied extensively in regards to 
glycogen content and the increased delivery of gluconeogenic substrate during sepsis 
(19,22).  Early studies have shown that when challenged with 51Cr –labeled E.coli 
endotoxin, the muscle contained no more than ~1% of the total radioactivity (15).  This 
observation suggests that glycogen changes in the muscle are secondary to those of liver 
glycogen changes due to the distribution of the endotoxin.  It has been previously 
observed that endotoxemia triggers a rapid depletion in skeletal muscle glycogen content 
(33), although skeletal muscle glucose uptake and skeletal muscle glucose clearance is 
increased following a bolus of LPS (69,71).  Buday et al. have shown that endotoxemic 
rats had 27% less glycogen in skeletal muscle and 86% less glycogen in the liver four-
hours after a bolus of endotoxin compared to basal (16).  This is thought to be associated 
with an increased phosphorylase a in both tissues compared to controls (16).  Glycogen 
repletion studies also demonstrated skeletal muscle was able to synthesize glycogen at 
similar rates when rats were infused with either saline or glucose following a four-hour 
endotoxemia study, whereas hepatic glycogen synthesis was reduced in rats infused with 
saline vs. the rats infused with glucose (16).   
 Little is known about the effects of glucagon on the response to endotoxin in vivo, 
although the likely hormonal effectors responsible for the fall in glycogen content are the 
elevated plasma concentrations of catecholamines and glucagon.  In studies where 
endotoxin treated rats were maintained either hypoglycemic or euglycemic with an 
infusion of glucose, glucagon remained elevated (increased by 24 fold and 9 fold; 
respectively) and insulin levels remained decreased (decreased 83% and 58%; 
respectively) (44).   
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 Other factors such as adrenal cortical hormones and protein C have been shown to 
play a role in the metabolic disequilibrium associated with endotoxemia.  Cortisone 
promotes glyconeogenesis and a negative nitrogen balance.  Early studies by Berry et al. 
showed that mice exposed to a lethal dose of endotoxin and then given a subcutaneous 
injection of 5 mg cortisone had an increase of 70% on average in survival rate over mice 
with a lethal dose alone (11).  Mice that survived a lethal dose of endotoxin in 
conjunction with the administration of cortisone had greater carbohydrate reserves than 
the mice with endotoxin challenge alone.  The survival rate associated with cortisone 
injection appears to be related to the ability of cortisone to allow for the favorable 
quantity of carbohydrate reserves remaining to sustain life.  The overall positive outcome 
of cortisone treatment during endotoxemia may also be associated with the anti-
inflammatory effects of this group of steroids (11). 
   
The Neuroendocrine Response to Endotoxin 
 There has been much controversy as to the specific role of epinephrine and 
norepinephrine in the response to an endotoxin challenge.  This controversy is due in part 
to the great differences observed to the response between animal and human models of 
sepsis.  It is thought that the catecholamine response to endotoxemia is similar in 
magnitude to the glucagon response, yet both have been hotly debated.  One fact remains 
constant across all experimental models- glycogenolysis is increased during sepsis 
primarily through the conversion of the inactive form of phosphorylase to the active 
form.  In large part, catecholamines, prostaglandin, and glucagon are responsible for this 
conversion (17).  The effects of catecholamines are wide ranging.  An intravenous bolus 
8 
of endotoxin decreases cardiac output in a dose dependent manner.  Although cardiac 
output is decreased, adrenal and hepatic arterial blood flows are markedly increased in 
guinea pigs (28).  This is important when taking into account the enhanced hepatic 
gluconeogenic rate and increased catecholamine and corticosterone synthesis by the 
adrenal glands during endotoxemia.  Conversely, the infusion of epinephrine in animals 
causes increased glucose turnover, gluconeogenesis, lactic acidemia, and transitory 
hyperglycemia, which are all hallmarks of endotoxemia (78).  Studies utilizing combined 
α- and β- adrenergic blockade by phentolamine and propranolol prevented the early 
transient hyperglycemia normally observed following an LPS bolus and either prevented 
or considerably attenuated the early increases in tissue glucose utilization (58).  The early 
increase in glucose uptake may be mainly attributed to adrenergic stimulation and the 
resultant hyperglycemia, while sustained elevation may be due to mechanisms 
independent of hyperglycemia (58).  Similar studies have also shown combined α- and β- 
adrenergic blockade completely prevents LPS induced increases in glucose production 
and glucose recycling, but blunts an increase in plasma lactate concentration and does not 
increase glucose clearance (78).  Combined adrenergic blockade also completely 
prevented the LPS induced increase in liver glucose uptake while there was a significant 
reduction in the spleen, intestine, skin, fat, and gastrocnemius (58).  Although glucagon is 
a vital metabolic hormone, it is interesting to note that, in rat studies that used a combined 
α- and β- adrenergic blockade, plasma glucagon concentrations were similarly elevated as 
in endotoxemic control rats, although the changes in carbohydrate metabolism were 
eliminated (78). 
 
9 
The Immune Response to Endotoxin 
 Serum proteins bind endotoxin, lead to the modification of endotoxic properties, 
and potentially induce detoxification in some circumstances.  It has also been established 
that small amounts of serum can enhance endotoxin binding and subsequent activation of 
cells.  The effects observed in endotoxin binding are related to a unique serum protein 
lipopolysaccharide-binding protein (LBP) (80).  LBP is a 60 kd serum glycoprotein that 
is synthesized in the hepatocytes of several species to include humans, mice, and rats 
(82).  LBP binds with high affinity to the lipid A portion of endotoxin causing the 
resulting complex to bind to either membrane bound CD14 (mCD14) or soluble CD14 
(sCD14) (82).  The endotoxin:LBP:mCD14 complex activates macrophages whereas the 
endotoxin:LBP:sCD14 complex reacts with endothelial and epithelial cells, leading to 
their activation and subsequent expression of cytokines and adhesion molecules (68).  
The liver is an important source of both LBP and sCD14 and thus plays a vital role in the 
clearing of endotoxin. 
 One of the consequences of endotoxin exposure is the circulating number of 
polymorphonuclear neutrophils (PMNs) is rapidly reduced and there is a subsequent 
sequestration of PMNs into the liver.  A state of neutropenia develops due to the rate of 
PMN removal from the circulation being greater than the increased rate of neutrophil 
entry into the blood (32).  The magnitude and duration of the neutropenia is dependent on 
the severity of the insult (43).  PMN accumulation in the liver adds a new group of 
nonparenchymal cells and is believed to occur as the result of chemotactic signals 
released by Kupffer cells (56,97).  The preferential localization of neutrophils is possibly 
related to the high rate of LPS clearance and rich population of macrophages within the 
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liver (52).  Stimulated PMNs actively secrete potent oxygen-derived radicals and 
destructive enzymes (defensins, lysozyme, collagenase, and lactoferrin) that can cause 
severe liver damage, which may contribute to the development of hepatic liver failure 
observed during severe sepsis (27).  It is believed that the specific chemotactic agents 
responsible for the induction and migration of PMNs are the C5a component of 
complement and leukotriene B4 (LTB4), although there is new evidence that TNF-α may 
also be a chemotactic candidate (73).  This is important because neutrophil adhesion 
plays an essential role in the progression of inflammation.  Hepatic injury may result 
from the increase in complement and TNF-α as these factors contribute to the 
upregulation of adhesion molecules on neutrophils (94).  Attempts have been made to 
eliminate neutrophils from the blood by using antibodies against the neturophils.  It has 
been observed that antibody-coated neutrophils disappear from the blood and accumulate 
mainly in the liver where they become functionally impaired and eliminated by resident 
macrophages (9).  Neutrophils may also pose a threat to liver tissue by becoming trapped 
in sinusoids due to the slightly smaller diameter of sinusoids compared to neutrophils.  
This may be exacerbated by the fact that endotoxin activation causes swelling of 
endothelial cells and Kupffer cells, which further decreases sinusoidal diameter. 
Both pro- and anti-inflammatory cytokines are upregulated during endotoxemia.  
Cytokines are generally released and act at the site of endotoxin insult but cytokine levels 
are elevated in the circulation and cytokines may be recruited to the area via chemotactic 
signaling.  TNF-α is typically the first cytokine to appear in the circulation after 
endotoxin challenge and typically peaks after 90 minutes (35).  There is a tight 
correlation between the magnitude of bacterial challenge and the extent of endotoxin 
11 
release.  The release of TNF-α is shortly followed by other proinflammatory cytokines 
including IL-1β, IL-6, IL-12 and IFN-γ (14).  The initial peak of TNF-α also triggers the 
release of several anti-inflammatory cytokines to include IL-10, IL-1ra, and soluble TNF-
α receptors (14).  During sepsis, the circulating concentrations of soluble TNF-α 
receptors and the naturally occurring IL-1 inhibitors, soluble IL-1 receptor type II and IL-
1ra, are increased substantially (89).  This increase may provide a means for the host to 
limit systemic TNF-α and IL-1β toxicity.   
During endotoxemia, circulating TNF-α, IL-1β, IL-6, epidermal growth factor, 
insulin-like growth factor, and fibroblast growth factor are cleared by the liver (2).  Up to 
30% of TNF-α is recovered in the liver within 15 minutes (the half-life of TNF-α) after 
intravenous injection.  IL-1β mRNA is greatly increased within 1-2 hours whereas the IL-
1 receptor antagonist (IL-1ra) mRNA peaks 2-4 hours following intravenous endotoxin 
challenge (85).  Although the half-life for IL-1β is 4 hours, it begins to collect in the liver 
within 20 minutes following endotoxin injection (39).  TNF-α and IL-β can induce the 
expression of IL-6 mRNA and an increase in IL-6 is generally detectable within 1 hour 
after endotoxin exposure.  IL-6 has a relatively short half-life of 1.5-3 minutes and up to 
80% of radiolabeled IL-6 from a single intravenous injection can be detected in the liver 
within 20 minutes (77).  The liver plays an important role in the inflammatory response to 
endotoxin but a striking caveat is that the liver may actually limit the beneficial systemic 
effects of these cytokines by clearing them prematurely. 
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The Role of Cytokines in Response to Endotoxin 
TNF-α and IL-1β share an extraordinary array of biological effects.  The systemic 
inflammatory effects of TNF-α include the induction of the cytokine network, the 
coagulation system, fibrinolysis, and neutrophils (88,90).  All of these are important in 
the regulation of the inflammatory response associated with sepsis.  IL-1β has been 
shown to induce similar effects without the activation of neutrophils.  It has been 
demonstrated that administration of high doses of either TNF-α or IL-1β to laboratory 
animals reproduces many characteristics observed in sepsis (63,83).  During sepsis, 
approximately 50% of radiolabeled endotoxin will accumulate in the liver within five 
minutes after an intravenous injection and the main site of accumulation is the Kupffer 
cells (52).  Rat Kupffer cells exposed to endotoxin produce TNF-α, and the addition of 
interferon-γ (IFN-γ) enhances the production of TNF-α (24).  If left unchecked, together 
IL-1β and TNF-α in excess can result in synergistic toxicity and have a lethal effect.  It is 
also important to note the cytokines TNF-α and IL-1β are responsible for most of the 
humoral modifications observed after endotoxin challenge (91). 
Glucose uptake is increased in the liver immediately following an endotoxin 
challenge.  Prior to endotoxin challenge, the Kupffer cells account for 25% of total 
hepatic glucose uptake in normal livers (67).  It is has been observed that glucose uptake 
is increased in macrophages and endothelial cells and remains constant in parenchymal 
cells immediately following an endotoxin insult (56).  Interestingly, TNF-α stimulates the 
same effect, leading one to speculate that this cytokine may play a crucial role in 
alterations in glucose uptake.  Experimental infusion of TNF-α increases glucose 
production without significantly increasing blood lactate concentration or causing a 
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hemodynamic response (7).  TNF-α infusion also increases plasma insulin, glucagon, and 
catecholamine concentrations (7) and increases glucose uptake in the liver, spleen, 
intestine, skin, and lung (57).  Thus, it is likely that cytokine release following endotoxin 
exposure may be one of the mechanisms by which endotoxin exerts its effects on glucose 
metabolism (57).  The hepatic immune response, IL-1β and TNF-α released by 
macrophages, is controlled by an increase in glucose uptake in Kupffer cells and is 
critical in the hepatic antibacterial defense against infection.  Alterations in any step of 
this process may have detrimental effects on the efficiency of the body to properly clear 
endotoxin.   
Early release of TNF-α appears to be essential in the role of the induction of both 
pro-and anti-inflammatory cytokines.  This has been demonstrated in experiments where 
anti-TNF-α antibodies given prior to endotoxin challenge blocks the increase in plasma 
and serum concentrations of IL-1β, IL-1ra, IL-6, IL-10, and soluble TNF-α receptors 
(12).  Unfortunately, this treatment is not realistic for the clinical setting as anti-TNF-α 
treatment is only protective against lethality when given before, simultaneously, or within 
30 minutes after a lethal dose of endotoxin exposure.   
Conversely, the anti-inflammatory cytokine IL-10 appears to have a protective 
function in models of endotoxemia.  Typically, anti-inflammatory cytokines inhibit the 
inflammatory process by aiding in the reduction of proinflammatory cytokine production.  
This has been shown in studies where recombinant IL-10 was injected directly prior to 
injecting mice with a lethal dose (LD100) of endotoxin.  The IL-10 injection markedly 
reduced TNF-α release and prevented lethality (30).  In humans, recombinant human IL-
10 has been observed to attenuate plasma TNF-α, IL-6, and IL-8 levels, the rise in body 
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temperature, and activation of the fibrinolytic system and coagulation system (65,66).  
The suppression of IL-10 by neutralization in septic mice results in an increase in the 
production of proinflammatory cytokines, including IFN-γ and TNF-α, and leads to death 
(49).  Similar results are also observed in IL-10 knockout mice exposed to endotoxin.  
These mice have increased mortality after endotoxin injection and elevated levels of 
TNF-α, IL-1β, IL-6, IL-12, and IFN-γ (44).  IL-10 proves to be an important part of the 
autoregulatory mechanism associated with controlling the production of proinflammatory 
cytokines and endotoxin associated toxicity in vivo. 
 
The Role of Interleukin-6 in Inflammation and Metabolism 
 IL-6 is found in the body as intracellular protein and circulating protein.  
Physiological stimuli for the synthesis of IL6 are IL-1, TNF, PDGF, oncostatin M, and 
bacterial endotoxin.  IL6 is also produced in the anterior lobe of the pituitary and can be 
induced by endotoxin and all substances responsible for elevating intracellular levels of 
cAMP.  The rate that IL-6 mRNA can be transcribed is affected by multiple transcription 
factors including Nf-κB.  The resulting IL-6 protein product can work in three ways: 1) in 
an autocrine manner whereby IL-6 can enhance the regulation of IL-6 in the infected 
local area, 2) in a paracrine manner whereby IL-6 can contribute to the inflammatory 
process in surrounding tissues, and 3) in an endocrine manner whereby IL-6 can send 
extracellular feedback messages to the brain and other organs via circulation through the 
blood stream.  Following a bolus of endotoxin, IL-6 protein enters the circulation and 
peaks within 60 minutes (29).  Major sites of IL-6 protein release are macrophage-rich 
tissues, such as the liver and spleen, and skeletal muscle and circulating IL-6 can be 
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elevated up to 300 fold during endotoxic insult (29,51).  IL-6 actions are mediated 
through binding with high affinity either to gp130 (a common form of cytokine signal 
transducer) membrane bound IL-6 receptors or to soluble IL-6 receptors.  The binding of 
IL-6 protein to either IL-6 receptor type leads to the formation of a gp130/gp130 
homodimer complex that in turn activates IL-6 signal transduction.  The soluble IL-6 
receptor is unique from other soluble cytokine receptors in that it serves an agonistic 
function once bound to IL-6 protein, allowing cells that lack a membrane bound IL-6 
receptor to be responsive to IL-6 (38).  IL-6 is responsible for a wide array of biological 
activities to include immunoglobulin production, proliferation and differentiation of T 
cells, enhancement of natural killer cell activities, maturation of megakaryocytes, and 
induction of acute-phase protein synthesis (38). 
The acute phase response in the liver is regulated by cytokines, glucocorticoids, 
and nitric oxide.  The primary cytokines that have been shown to be involved in this 
regulation are IL-1β (60), TNF-α (75), and IL-6 (34).  Neither TNF-α nor IL-1β is 
capable of regulating a complete acute response, although adequate regulation can be 
accomplished indirectly by TNF-α in the presence of glucocorticoids or IL-6 (8).  On the 
contrary, IL-6 is the most important cytokine with regard to the acute phase response as it 
is the only cytokine capable of inducing an almost complete response (34).  It is possible 
circulating IL-6 and IL-6 derived from peripheral macrophages, Kupffer cells, and 
hepatocytes are responsible for the acute response.  Regardless, IL-6 requires the 
presence of glucocorticoids to achieve the maximal and complete acute phase response.  
IL-6 regulates the acute-phase protein response by stimulating hepatocytes to produce 
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acute phase reactants such as C-reactive protein, serum amyloid A, α1-acid glycoprotein, 
α1-antitrypsin, and fibrinogen.   
IL-6 is most commonly recognized as a proinflammatory cytokine due to its role 
during exaggerated inflammatory states such as severe sepsis and type II diabetes.  
Nearly all published clinical studies involving severe sepsis and cytokine levels have 
found a positive correlation between IL-6 concentrations on admission and mortality 
(64).  Although IL-6 is typically considered a proinflammatory cytokine, it has anti-
inflammatory properties as well, making this cytokine unique.  Multiple studies have 
been conducted to elucidate the role of IL-6 has in mediating hormonal and 
immunological changes both in vivo and in vitro.  In clinical studies, intravenously 
infused IL-6 produces mild clinical symptoms such as fever and chills, but it is not nearly 
as toxic as TNF-α and IL-1β.  The anti-inflammatory effects of IL-6 are demonstrated by 
its ability to inhibit endotoxin-induced TNF-α and IL-1β production by mononuclear cells 
in vitro and to reduce TNF-α release in endotoxemic mice in vivo (1).  IL-6 has also been 
shown to induce an increase in plasma levels of naturally occurring inhibitors of TNF-α 
and IL-1β in the form of soluble TNF-α receptor type I and IL-1ra (81).   
Metabolic studies conducted in vitro using HepG2 cells and primary mouse 
hepatocytes that were acutely pretreated with IL-6 demonstrate impaired insulin receptor 
signaling as well as impaired insulin-dependent glycogen synthesis (74).  In vivo studies 
using a short-term infusion of IL-6 in humans have shown increases in circulating free 
fatty acids, and the increase in IL-6 may inhibit the negative effects of TNF-α, thus 
indirectly promoting glucose uptake and enhancing insulin sensitivity in peripheral 
tissues (29).  A bolus injection of IL-6 in rats has been shown to produce a transient 
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increase in plasma glucagon and increase plasma glucose and insulin levels after 90 
minutes, and it is believed that the increase in the plasma insulin level was due to the 
increase in glucose and not the IL-6 (79).  Similarly, fasting glucose levels were 
increased in a dose dependent manner in healthy human subjects within 60 minutes 
following a bolus of IL-6 (84).  Glucagon levels increased significantly and peaked 
between 120 to 150 minutes following the IL-6 bolus (84).  Chronic IL-6 infusion 
reduces hepatic insulin autophosphorylation and tyrosine phosphorylation of both insulin 
receptor substrates-1 and -2 (40).  In these studies, insulin tolerance tests revealed 
reduced insulin sensitivity, yet the chronic infusion of IL-6 failed to suppress skeletal 
muscle insulin receptor signal transduction, suggesting that chronically elevated IL-6 
selectively impairs hepatic insulin signaling in vivo.  Likewise, it has been observed that 
IL-6 blockade by anti-IL-6 antibodies can be protective in sepsis (70).  The 
administration of anti-IL-6 antibodies shortly after the initiation of cecal ligation and 
puncture inhibits C5a receptor mRNA expression during the onset of sepsis and 
significantly improves survival (70). 
As one might expect, the unique pro- and anti-inflammatory nature of IL-6 adds 
many layers of complexity to discerning its role in a pathogenic state such as sepsis.  
There is a profound lack of data correlating the interaction of increased levels of IL-6 
during sepsis with alterations in carbohydrate metabolism.  Current studies have only 
begun to touch the tip of the iceberg. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animal Care and Husbandry 
 All procedures were approved by the Vanderbilt University Animal Care and Use 
Committee and followed NIH guidelines for the care and use of laboratory animals.  All 
experiments were performed on mice with the C57BL/6J background between four and 
five months of age.  Mice were weaned at three weeks of age and separated by sex.  Mice 
were identified by ear punching, and a tail biopsy was taken with the purpose of 
obtaining a genomic DNA sample.  Genotyping was performed by polymerase chain 
reaction (PCR) on DNA isolated by a DNeasy Tissue Kit (Qiagen, Valencia, CA).  PCR 
primer sequences used for the genetic models were obtained from Jackson Laboratories.  
Mice were housed in an environment with five mice per micro-isolator cage.  Mice were 
maintained on a light cycle of 0700-1900 at 23°C and were allowed free access to Purina 
5001 laboratory rodent chow diet and water.   
  
Mouse Models 
 Interleukin-6 knockout mice have no interleukin-6 mRNA and protein expression 
(41).  Mouse models with both the presence and absence of IL-6 mRNA and protein 
expression were utilized for all experiments.  IL-6 knockout mice (IL-6-/-) on a C57BL/6 
background (Jackson Laboratories, Bar Harbor, ME) were bred to C57BL/6J mice 
(Jackson Laboratories, Bar Harbor, ME) to yield heterozygous pups (IL-6+/-).  Male and 
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female IL-6+/- mice were bred to generate Mendellian litters.  IL-6-/- , IL-6+/- and IL-6+/+ 
genotypes were confirmed by PCR utilizing primer sequences obtained from JAX 
(Jackson Laboratories, Bar Harbor, ME) in accordance with original forward, reverse and 
NEO primers originally published by Kopf et al. (41).  Mice of both genders were utilized 
for all studies.  IL-6+/- mice were used to continue breeding schemes mentioned above.   
 
Surgical Procedures 
 Mice were anesthetized with an intraperitoneal injection of pentobarbital 
(70mg/kg body weight).  Following administration of anesthesia, the skin on the 
interscapula and on the right and left sides of the neck was shaved and sterilized with 
10% povidone-iodine.  Surgery was initiated with loss of foot withdrawal and corneal 
blinking reflex. 
 The left common carotid artery was catheterized for the sampling of well-mixed 
arterial blood with a two-part catheter consisting of modified PE-10 tubing (inserted into 
the artery) connected to silastic tubing (0.025 in OD).  The PE-10 was stretched by 
heating under sterile water and then quickly chilled in order to decrease the diameter.  
The PE-10 was then inserted approximately 2mm into the silastic tubing and beveled at 
45° on the exposed end.  A small skin incision (~5mm) was made approximately 3mm 
adjacent to the trachea.  The common carotid artery was isolated and separated from the 
vagus nerve and surrounding muscle.  Two thin threads of silk (6-0 Silk, Davis+Geck, 
Wayne, NJ) were passed under the artery.  The cephalic thread was tied to prevent 
bleeding and then the artery was clamped with a small bulldog clamp.  A small incision 
was made just below the ligature and the catheter was inserted into the lumen.  The 
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modified PE-10 was inserted approximately 9mm into the left common carotid artery 
such that the catheter tip was near the aortic arch.  The catheter was fixed with a second 
thread and the thread previously used to prevent bleeding in order to secure the catheter 
in place.  The bulldog clamp was removed to verify the proper function of the catheter. 
 The right jugular vein was catheterized for infusions with a silastic catheter (0.025 
in OD).  A small longitudinal incision (~5mm) was made in the skin just over the 
location where the anterior jugular, acromiodeltoid, and cephalic veins join.  The 
connective tissues surrounding this junction were carefully removed.  Two thin threads of 
silk (6-0 Silk, Davis+Geck, Wayne, NJ) were passed under the jugular vein below the 
level of the junction and separated by about 3 mm.  The cephalic thread was placed just 
below the joint and was tied to prevent bleeding.  A small incision was then made just 
below the ligature and the catheter was inserted into the lumen and advanced ~13 mm.  
The catheter was secured with the second thread and with the free ends of the cephalic 
thread were used to anchor the catheter in place. 
 The free ends of the catheters were tunneled under the skin to the back of the neck 
with a blunt 16 gauge needle, where the loose ends of the catheters were attached via 
stainless steel connectors to tubing made of Micro-Renathane (0.033 in OD), which were 
exteriorized and sealed with stainless steel plugs.  Mice were moved to a warming bed 
following surgery and were observed until they were fully awake.  Both lines were 
flushed daily with ~50 µl of saline containing 200 U/ml of heparin and 5 mg/ml of 
ampicillin.  Animals were individually housed after surgery and body weight was 
recorded daily.  
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In Vivo Metabolic Experiments 
 All metabolic experiments were performed following a ~7 day postoperative 
recovery period.  The recovery period was deemed sufficient when body weight was 
restored within 10% of pre-surgery body weight.  On the day of the study conscious, 
unrestrained mice were placed in ~1 L plastic container lined with bedding and fasted for 
5 h.  Approximately 2 h prior to an experiment, Micro-Renathane (0.033 in OD) tubing 
was connected to the catheter leads and infusion syringes.  A 5 µCi ( 100 µL) bolus of 3-
[3H]-D-glucose was given followed by a constant infusion at a rate of 0.05 μCi/min 
(NEN, #NET331C; 1 uL/min).  Approximately 1 h prior to an experiment, red blood cells 
from a donor mouse on a C57Bl/6J background were washed with 0.9% heparinized 
saline and infused at a rate of 2 µl/min for the duration of the study to minimize the fall in 
the hematocrit (<5%)).  Following the 2 h equilibrium period, a baseline arterial blood 
sample (230 µl) was drawn for the measurement of arterial blood glucose, 3-[3H]-D-
glucose, hematocrit, plasma insulin, plasma glucagon, catecholamines and cytokines.   
 
LPS Experiments in IL-6-/-, IL-6+/-, and IL-6+/+ Mice 
 The maximum effects of IL-6 during an LPS challenge can be observed between 
180 and 360 min (29,77).  For this reason, the current study design assesses the effect of 
LPS over a time period of 265 min (Figure 1).  Approximately 5 min following the 
baseline arterial blood sampling, mice were given a 250 µg/mouse bolus of E.coli 
(serotype 0111:B5) endotoxin (Sigma, St. Louis, MO) followed by 25µL saline and the 
clock was reset (t = 0 min) (Figure 3a).  At t = 30 min, arterial blood (~230 µL) was 
sampled in order to determine arterial blood glucose, 3-[3H]-D-glucose, hematocrit, 
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plasma insulin, plasma glucagon, catecholamines and cytokines.  At t = 60 and 120 min, 
arterial blood (~10 µL) was sampled in order to assess the arterial blood glucose 
concentration.  At t = 180 and 240 min, arterial blood (~70 µL) was sampled in order to 
determine arterial blood glucose,  3-[3H]-D-glucose, and cytokine levels.  And at t = 210 
min, arterial blood (~30 µL) was sampled in order to determine arterial blood glucose and 
3-[3H]-D-glucose concentrations.  
 Shortly after the t = 240 sampling, a 13 µCi bolus of 2-deoxy[14C]glucose ([2-
14C]DG) was administered in order to determine Rg and the clock was reset.  Arterial 
blood (~30 µL) was sampled to assess blood glucose and plasma 3-[3H]-D-glucose and 
[2-14C]DG concentration 2, 5, 10, and 15 min after the bolus was given.  At  25 min after 
the bolus (t = 265 for length of study), a final arterial blood sample (~230 µL) was taken 
and processed in the same manner as the baseline blood sample  with the addition of the 
determination of plasma [2-14C]DG.  Following the last arterial blood sample, mice were 
anesthetized and the soleus, gastrocnemius, superficial vastus lateralis (SVL), omental 
adipose tissue, liver, kidney, duodenum, jejunum, diaphragm, heart, subcutaneous 
adipose tissue and brain were excised, immediately frozen in liquid nitrogen, and stored 
at -70°C until future tissue analysis.   
 
LPS Experiments with Replacement of Interleukin-6 in IL-6-/- Mice 
 For LPS experiments the interleukin-6 replacement in IL-6-/- mice, studies were 
carried out exactly the same as the previous LPS studies with the following exceptions 
(Figure 2).  Approximately 5 min following the baseline arterial blood sampling,   IL-6-/- 
mice were given a 250 µg/mouse bolus of E.coli (serotype 0111:B5) endotoxin followed 
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by 25µL saline.  Immediately following the bolus of endotoxin, a constant infusion of 
rmIL-6 (16 µg/hr) (Research Diagnostics, Inc., Flanders, NJ) at a rate of 1 µL/min was 
started and the clock was reset (t = 0 min) (Figure 3b).  At t = 30 min, arterial blood 
(~230 µL) was sampled in order to determine arterial blood glucose, 3-[3H]-D-glucose, 
hematocrit, plasma insulin, plasma glucagon, catecholamines and cytokines.  
Immediately following the t = 30 arterial blood sample, the pump rate of the rmIL-6 was 
increased to 2 µL/min in order to simulate the natural IL-6 response observed in wild type 
animals.  At t = 60 and 120 min, arterial blood (~10 µL) was sampled in order to assess 
the arterial blood glucose concentration.  At t = 180 and 240 min, arterial blood (~70 µL) 
was sampled in order to determine arterial blood glucose,  3-[3H]-D-glucose, and 
cytokine levels.  At t = 210 min, arterial blood (~30 µL) was sampled in order to 
determine arterial blood glucose and 3-[3H]-D-glucose concentrations.  
  
Processing of Plasma and Muscle Samples 
Blood Glucose Concentration 
 Whole blood glucose concentration was measured on arterial blood samples 
during all metabolic studies at the time points indicated in figures 1 and 2.  For 
determining blood glucose concentration, ~10 µL of arterial blood was collected into a 
HemoCue B-Glucose Microcuvette and measured on a HemoCue B-Glucose Analyzer 
(HemoCue, Mission Viejo, CA).  The HemoCue Analyzer used in these studies was 
calibrated daily using the standardized control Microcuvette provided with the analyzer.  
The theory of this assay is based on two concepts, hemolysis and a glucose reaction.  
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Saponin in the cuvette lyses the erythrocytes and partially dissolves the membranes.  The 
following is a depiction of the reactions used to determine the glucose concentration: 
mutarotase 
α-D-glucose    β-D-glucose 
 
glucose dehydrogenase 
             β-D-glucose + NAD    D-gluconolactone + NADH 
 
diaphorase + NADH 
                                           MTT    formazan 
 
whereas MTT is the tetrazolium salt 3-[4,5-dimethylthiazol-2yl-]-2,5-diphenyltetrazolium 
bromide.  Formazan is measured spectrophotometrically at 660 and 840 nm. 
 
Plasma Immunoreactive Insulin 
 Immunoreactive insulin was measured on the baseline plasma sample as well as 
on plasma samples obtained at t = 30 and 265 min in all metabolic experiments.  The 
assay uses a Linco Rat Insulin Radioimmunoassay (RIA) kit (Linco Research, Inc., St. 
Charles, MO) and a double antibody method (59).  50 µL plasma samples are incubated 
with 125I-rat insulin and a guinea pig anti-rat insulin primary antibody that equally cross 
reacts with mouse and porcine insulin.  The labeled and unlabeled insulin compete for the 
limited number of antibody binding sites.  If the amount of unlabeled insulin is increased, 
there will be a decrease in the amount of labeled insulin binding to the antibody.  Insulin 
bound by the primary antibody was precipitated with a secondary antibody.  Following 
centrifugation and decanting, pellets were counted in a Cobra II Auto-Gamma counter 
(Packard Instrument Co., Downers Grove, IL).  The insulin concentration in the sample 
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was inversely proportional to the radioactivity in the pellet.  Insulin concentrations were 
determined using a standard curve generated from known concentrations of insulin and 
resultant radioactivities.  Samples were corrected for non-specific binding.  Controls 
consisted of two commercial and four in-house controls for each RIA. 
 
Plasma Glucagon  
 Immunoreactive glucagon was measured on the baseline plasma sample as well as 
on plasma samples obtained at t = 30 and 265 min in all metabolic experiments.  The 
assay uses a Linco Rat glucagon (RIA) kit (Linco Research, Inc., St. Charles, MO) and a 
double antibody method (61).  50 µL plasma samples are incubated with 125I-rat glucagon 
and a guinea pig anti-rat glucagon primary antibody that equally cross reacts with mouse, 
rat, rabbit, hamster, pig, cow, camel, monkey and human glucagon.  The labeled and 
unlabeled glucagon compete for the limited number of antibody binding sites.  If the 
amount of unlabeled glucagon is increased, there will be a decrease in the amount of 
labeled glucagon binding to the antibody.  Glucagon bound by the primary antibody was 
precipitated with a secondary antibody.  Following centrifugation and decanting, pellets 
were counted in a Cobra II Auto-Gamma counter (Packard Instrument Co., Downers 
Grove, IL).  The glucagon concentration in the sample was inversely proportional to the 
radioactivity in the pellet.  Glucagon concentrations were determined using a standard 
curve generated from known concentrations of glucagon and resultant radioactivities.  
Samples were corrected for non-specific binding.  Controls consisted of two commercial 
and four in-house controls for each RIA. 
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Epinephrine and Norepinephrine 
 Plasma epinephrine and norepinephrine content was assessed by high 
performance liquid chromatography with electrochemical detection (HPLC/EC) (31) after 
alumina extraction (4), elution and pre-concentration.  50 µL of glutathione and EDTA 
preserved plasma was absorbed onto alumina at a basic pH of 8.6.  The solution was 
shaken and centrifuged and the supernatant was removed.  The alumina pellet was then 
rinsed with three deionized-water washings to remove contaminants.  The catecholamines 
were then eluted from the alumina with 0.1M perchloric acid (PCA), the samples were 
centrifuged and the supernatant was again rinsed with PCA. 
The samples were injected onto a HR-80, reverse phase, 3 µm octadecylisilane 
column and run on the Coulochem II (ESA, Bedford, MA) electrochemical detector.  
Potentials were optimized by exposure to an electric field.  Recovery was calculated from 
the ratio of 2,3-dihydroxybenzoic acid (DHBA) and standard peak heights in the 
injection.  A standard curve from known concentrations was utilized for each hormone. 
 
Plasma Cytokine Concentration 
 Cytokines were analyzed for all metabolic experiments using the bead-based 
multiplexing Luminex xMAP technology (Luminex, Austin, TX).  Luminex color-coded 
tiny beads, called microspheres, into four distinct sets.  Each bead set was coated with 
either IL-6, IL-1β, IL-10, or TNF-α antibodies, allowing the capture and detection of 
specific cytokines from a sample.  Within the Luminex 100 analyzer, lasers excite the 
internal dyes that identify each microsphere particle, and any reporter dye captured 
during the assay.  Many readings are made on each bead set, further validating the results.  
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In this way, xMAP technology allows multiplexing of all four cytokines within a single 
sample (Luminex corp).   
 Plasma samples were prepared using a mouse cytokine/chemokine Lincoplex kit 
(Linco Research, St. Charles, MO).  A 96-well filter plate was prepared by blocking the 
wells with 200 µL assay buffer.  Prepared standards, controls and 25µL of plasma were 
pipetted into prepared wells.  25µL of an antibody bead mixture containing beads specific 
for IL-6, IL-1β, IL-10 and TNF-α were pipetted into each well and placed on a plate 
shaker in the cold room overnight to optimize antibody binding.  The plate was washed 
with 200 µL/well wash buffer and 25 µL detection antibody and 25 µL streptavidin-
phycoerythrin was added to each well.  The plate was placed on a plate shaker at room 
temperature for 30 min and the contents were vacuumed off.  The plate was washed three 
times with 200 µL/well wash buffer and 100 µL/well sheath fluid was added to each well.  
The plate was counted on the Luminex 100 analyzer.  All samples were fit to a logistical 
5-spline curve specific for each cytokine.  
 
Plasma Radioactivity 
 Plasma samples were deproteinized with 100 µL of barium hydroxide [Ba(OH)2, 
0.3 N] and 100 µL zinc sulfate [ZnSO4, 0.3 N] as described by Somogyi (76).  Samples 
were centrifuged (Hercules Biofuge Fresco, Kendro Laboratory Products, Germany) for 5 
min at 13,000 rpm.  Two samples were prepared for each time point.  First, 100 µL was 
pipetted directly into glass scintillation vials along with 900 µL double distilled water and 
10 mL of Ecolite+ scintillation fluid (ICN Biomedicals, Costa Mesa, CA).  For the 
second sample, 100 µL were pipetted into glass scintillation vials and were evaporated at 
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50°C in a vacuum oven (Lab-line Instruments, Inc., Melrose Park, IL) to remove tritiated 
water.  The dried residue was dissolved in 1 mL of double distilled water and 10 mL of 
Ecolite+.  The [3H] and [14C] radioactivity was determined by double label liquid 
scintillation counting (Beckman LS 3801; Beckman Instruments, Inc., Irvine, CA) for 10 
min.  Quenching occurs when quenching agents in the sample cause a left shift of the 
energy spectrum.  Thus, the scintillation counter was programmed to correct for the error 
caused by quenching.  Quenching curves were created such that counts per minute (cpm) 
were converted to disintegrations per minute (dpm) by subtracting background cpm and 
then dividing by the counting efficiency for each sample.  Data was corrected for 
spillover.     
 Recovery standards were prepared in order to determine the recovery of 
radioactive glucose during the deproteinization step.  The 3-[3H]-glucose infusate was 
diluted 1:200 (v:v) with saturated benzoic acid.  The radioactivity was assessed in three 
types of standards.  First, 100 µL of the diluted infusate (chemical standard, CS) with 10 
mL of Ecolite+ was counted in triplicate.  Second, 100 µL of diluted infusate was 
evaporated (chemical standard evaporated, CSE) in triplicate to ensure that [3H] H2O was 
removed from the sample.  The dried residue was dissolved in 1 mL of double distilled 
water and 10 mL of Ecolite+.  Finally, 100 µL of diluted infusate was treated in the same 
manner as the plasma samples (chemical recovery standard, CRS) by following the same 
deproteinization steps as outlined above.  Recovery of radioactivity was calculated as the 
ratio of CSE to CRS, and all samples were corrected using this ratio. 
 14C radioactivity was calculated on arterial plasma samples during the last 25 min 
of all metabolic studies in order to quantify the disappearance of [2-14C]DG from the 
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plasma.  [2-14C]DG standards were prepared in order to determine the recovery of 
radioactive 2-deoxy-glucose.  In short, 4 µL of [2-14C]DG infusate was diluted 1:50 (v:v) 
with saline (mixture A).  50 µL of mixture A was diluted 1:20 (v:v) with dd water 
(mixture B) and 100 µL of mixture B was added to a glass scintillation vial with 900 µL 
dd water and 10 mL Ecolite+ scintillation fluid and counted. 
 
Tissue Radioactivity 
 14C radioactivity was determined independently on all tissues excised during all 
metabolic studies.  Tissues were kept frozen while being weighed and homogenized in 
1.5 mL of 0.5% perchloric acid.  Homogenates were centrifuged (Beckman GS-6R, 
Beckman Instruments Inc., Irvine, CA) for 20 min at 3500rpm and 1.25 mL were pipetted 
into a fresh tube and neutralized to ~7.5pH with KOH.  One aliquot from each tissue was 
counted directly to determine the combined [2-14C]DG and [2-14C]DG-6-phosphate ([2-
14C]DGP) radioactivity.  A second aliquot from each tissue was treated with Ba(OH)2 and 
ZnSO4 to remove [2-14C]DGP and any tracer incorporated in to glycogen (55) and then 
counted to determine [2-14C]DG radioactivity.  The value for [2-14C]DGP is determined 
by subtracting the dpm value for [2-14C]DG + [2-14C]DGP from the dpm value for [2-
14C]DG.  The accumulation of [2-14C]DGP was normalized to tissue weight for each 
experiment. 
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Calculations 
Glucose Turnover 
 The definition of glucose turnover is the rate of old glucose that is replaced by 
new glucose.  Radioactively tagged glucose is used as a means to measure glucose 
turnover.  In order to validate glucose turnover, several things must be assumed.  It is 
important that the selected model of glucose kinetics is valid, the radioactively labeled 
and unlabeled glucose molecules are metabolized in the same manner, the measurement 
of glucose specific activity (SA) is accurate, and the radioactive label is irreversibly lost 
in the metabolism of the molecule. 
 In all metabolic experiments, the glucose pool was initially primed with a bolus of 
tracer (3-[3H]-glucose) followed by a constant infusion of tracer.  The purpose of priming 
the pool is so that an equilibrium between the tracer and tracee (endogenous non-labeled 
glucose) is established thus allowing SA (dpm/mg) to be in a steady state.  Glucose 
turnover or production (Ra, rate of appearance) was calculated as the ratio of the tracer 
infusion rate and its SA in accordance with the following non-steady state equation: 
   Ra = [I – M (δSA/δt)]/SA     (1) 
where I is the tracer infusion rate (dpm/min), M is the mass of the pool of glucose (mg) 
and t is time (min).   
Whole-body glucose utilization (Rd, rate of disappearance) was calculated using 
the following equation: 
   Rd = Ra – (Vd) (δA/δt)      (2) 
whereas Vd is the volume of distribution (mL/kg) of glucose.  A value of 130 mL/kg is 
used in these calculations.  A is the whole body glucose concentration and δA/δt is its 
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derivative (50).  Under no circumstance can δA/δt be assumed to be zero in the non-
steady state.  Tracer-determined Ra and Rd were calculated according to the method of 
Wall et al. (92) as simplified by De Bodo et al. (23). 
 
Glucose Clearance 
 Glucose clearance is used to assess the ability of peripheral tissues to remove 
glucose from the plasma in a manner that is independent of glucose concentration.  
Glucose clearance was calculated as follows: 
   clearance = Rd / [glucose]arterial    (3) 
where [glucose]arterial is the average blood glucose (mM) during the experimental period. 
 
Tissue Glucose Uptake 
 Tissue glucose uptake is an index of how well the periphery clears glucose from 
the plasma under a certain metabolic state.  Both concentration independent (Ri) and 
concentration dependent (Rg) indices of tissue glucose uptake were calculated according 
to the method of Kraegen et al. (42).  Ri and Rg were calculated as follows: 
   Ri = [2-14C]DGPtissue/AUC [2-14C]DGplasma   (4) 
   Rg = (Ri ) ([glucose]plasma)     (5) 
whereas [2-14C]DGPtissue is the [2-14C]DGP radioactivity (dpm/g) in the tissue, AUC [2-
14C]DGplasma is the area under the plasma [2-14C]DG disappearance curve (dpm/mL/min), 
and [glucose]plasma is the average blood glucose (mM) during the experimental period.   
 All counts were normalized by standard infusate radioactivity before calculating 
Ri and Rg.   
32 
Statistical Analysis 
 Power calculations were conducted and it was determined that at least 8 animals 
were required per group to obtain sufficient statistical power to detect differences among 
the groups.  All data are presented as mean ± SEM.  Differences between groups were 
determined by ANOVA or repeated measures ANOVA when appropriate.  The 
significance level was set at 0.05 (Sigma Stat, Port Richmond, CA).   
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CHAPTER III 
THE IMPACT OF INTERLEUKIN-6 ON THE METABOLIC RESPONSE TO 
ENDOTOXIN in vivo 
Specific Aims 
 The goal of this study was to examine the impact of Interleukin-6 (IL-6) on the 
metabolic response to endotoxin in vivo.  The specific goals of this study were:  1) To 
characterize the metabolic response to endotoxin in the presence or absence of the IL-6 
protein, and 2) To test whether the metabolic esponse to endotoxin observed in wild type 
mice can be recapitulated by infusing physiological levels of rmIL-6 into IL-6 knockout 
mice
 
groups (144±14, 145±9, 158±6 mg/dl; respectively), but IL-6+/+ (WT) mice had a 
ignificantly lower basal arterial blood glucose concentration (102±11 mg/dl; P<0.005) 
(Figures 4 and 16).  Following t  endotoxin, arterial blood glucose 
  
rterial blood glucose fell below baseline for all groups by 240 min, with the WT group 
reaching glucose concentrations deemed hypoglycemic (70±8 mg/dl; WT).   
 
 r
.   
Hypothesis 
 The absence of IL-6 attenuates the hypoglycemic response to acute endotoxemia. 
 
Results 
Glucose Metabolism:  The arterial blood glucose concentrations were similar during the 
basal period in the IL-6 +/- (HET), IL-6 -/- (KO), and IL-6 -/- with rmIL-6 replacement (KO 
+ IL-6) 
s
he bolus of
concentrations increased in all groups, with the largest increase noticeable at 60 min.
A
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 Ra (Figures 5 and 17), Rd (Figures 6 and 18), and glucose clearance (Figures 7 and 
19) were calculated using a non-steady state equation.  Basal conditions can be 
considered steady state since the animal was not experiencing any sudden changes in Ra, 
Rd, clearance, or metabolism.  Therefore, all groups had similar basal values for Rd as 
observed for Ra since Rd = Ra in steady state conditions.  During basal conditions, 
glucose clearance was similar in all groups.   
KO displayed similar glucose clearance patterns as KO + IL-6 within the first 30 
min (Figure 7).  During this time, the rate of glucose clearance decreased in both of these 
groups.  Ra remained comparatively unchanged over basal values in both groups. 
The most profound changes in arterial glucose occurred between 30 and 180 min 
following the LPS bolus.  During this time, Ra and Rd were matched in all groups.  There 
was little change in Ra, Rd, and clearance in WT and HET, while KO experienced a 
significant change in both Ra and Rd (P<0.010) that was accompanied by an increase in 
glucose clearance (P<0.037) over the 30 min time period.   
During the 180 to 210 min time period, arterial glucose was below baseline in all 
groups and glucose clearance was increased in all groups with the greatest increase 
occurring in HET and KO + IL-6 (P<0.003).   
By the end of the study, Ra and Rd were equivalent in all groups and were similar 
to values observed during the basal period.  Glucose clearance remained unchanged 
compared with values observed in the 180 to 210 time period.    
Cytokine Concentration:  Blood IL-6 levels rose simultaneously in WT and HET 
(386±138 to 14606±404 to 14880±653 and 21±6 to 14313±476 to 14050±543pg/ml; 
respectively; basal to 180 to 275 min), although HET experienced a delayed rise 
37 
compar
other cytokine, hormonal, and metabolic 
pattern
23).  Conversely, the rise in TNF-α in HET, KO, and KO + IL-6 did not 
ed to WT (Figure 20).  As expected, IL-6 in KO was undetectable throughout the 
length of the study.  The goal of the KO + IL-6 study was to recapitulate the levels of IL-
6 observed in WT with the hypothesis that 
s would in turn mimic that of WT.  The IL-6 profile in KO + IL-6 (12±6 to 
14089±376 to 14402±283 pg/mL; basal to 180 to 275 min) was successfully matched to 
WT (Figure 8). 
 IL-1 was at the lower limits of detection in the basal period in all groups.  IL-1 
levels increased by 180 min and were similar in all groups.  These levels continued to rise 
at the end of the study, with the largest difference being between HET and KO + IL-6 
(436±97 and 262±63 pg/mL; respectively) (Figures 9 and 21). 
 TNF-α and IL-10 were low in the basal period in all groups.  The increase 
observed at 180 min was equal among all groups in both TNF-α and IL-10.  Interestingly, 
WT was the only group that experienced a rapid increase in TNF-α at 30 min (Figures 10 
and 22) and KO was the only group that experienced a rapid increase in IL-10 by 30 min 
(Figures 11 and 
reach ~1000 pg/mL by 30 min.  IL-10 remained equally elevated in all groups at the end 
of the study.  TNF-α remained equally elevated at the end of the study in WT, HET, and 
KO + IL-6 whereas KO was the only group that actually declined. 
  
Hormone Concentration: The insulin concentration was nearly the same in all groups at 
the basal time point although KO had a higher basal insulin level (P<0.032) (Figure 12).  
Insulin levels in HET and WT were matched (0.22±0.05 and 0.21±0.03 ng/mL, 
respectively) (Figure 24) while KO had the most dramatic decrease over basal of any 
38 
group (0.41±0.07 ng/mL).  KO + IL-6 displayed an intermediate insulin value at the end 
of the study (0.31±0.09 ng/mL) (Figure 12). 
 Glucagon was similar in all groups except for WT at the basal time point (157±29, 
68±11, 53±10, and 72±16, and pg/mL; WT, HET, KO, and KO + IL-6 respectively) 
(Figures 13 and 25).  By the end of the study, there was very little change in glucagon in 
WT, KO and KO + IL-6, with the greatest increase over basal being in HET. 
 Epinephrine was at the lower limits of the assay in all groups at the basal time 
point.  All groups experienced a rise in epinephrine at 30 min.  By the end of the study, 
epinephrine values were equal to values observed at 30 min in HET, KO, and KO + IL6 
(114±47, 109±40, and 63±19 pg/mL; respectively) and significantly higher in WT 
(439±115 pg/mL; P<0.001) at 275 min (Figures 14 and 26).   
 Norepinephrine was also variable in all groups at the basal time point with WT 
than HET and KO + IL-6 (259±74 and 226±26 pg/mL; respectively; P<0.050).  At 30 
min, all groups were the same and this remained the case until the end of the study 
(Figures 15 and 27). 
 
 
 
 
 
 
and KO (124±26 and 137±19 pg/mL; respectively) values being significantly different 
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igure 5:  The rate of glucose production (Ra) in mg/kg/min in WT, KO, and KO + 
-6.  Data are expressed as mean ± SE.  * P<0.050 
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igure 6:  The rate of glucose utilization (
-6.  Data are expressed as mean ± SE. 
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igure 7:  The rate of glucose clearanc
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igure 8:  The plasma concentration of Interleukin-6 (IL-6) in pg/mL in WT, KO, 
nd KO + IL-6.  Data are expressed as mean ± SE. 
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igure 9:  The plasma concentration of Interleukin-1β in pg/mL in WT, KO, and 
O + IL-6.  Data are expressed as mean ± SE. 
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igure 11:  The plasma concentration of Interleukin-10 (IL-10) in pg/mL in WT, 
O, and KO + IL-6.  Data are expressed as mean ± SE. 
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igure 12:
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igure 14:  The plasma concentration of epinephrine in pg/mL in WT, 
O + IL-6.  Data are expressed as mean ± SE.  * P<0.050 
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igure 15:  The plasma concentration of norepinephrine in pg/mL in WT, KO, 
nd KO + IL-6.  Data are expressed as mean ± SE.  * P<0.050 
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igure 17:  The rate of glucose production (Ra) in mg/kg/min in WT and HET.  
ata are expressed as mean ± SE. 
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igure 18:  The rate of glucose utilization (Rd) in mg/kg/min in WT and HET.  
ata are expressed as mean ± SE. 
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igure 19:  The rate of glucose c
xpressed as mean ± SE.  * P<0.
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igure 21:  The plasma concentration of Interleukin-1β in pg/mL in WT and HET.  
ata are expressed as mean ± SE. 
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igure 23:  The plasma concentration of Interleukin-10 (IL-10) in pg/mL in WT 
nd HET.  Data are expressed as mean ± SE. 
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igure 24:  The plasma concentration of insulin in ng/mL in WT and HET.  Data 
re expressed as mean ± SE. 
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igure 26:  The plasma concentration of epinephrine in pg/mL in WT and HET.  
ata are expressed as mean ± SE.  * P<0.050 
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igure 27:  The plasma concentration of norepinephrine in pg/mL in WT and 
ET.  Data are expressed as mean ± SE. 
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Discussion 
 It was our hypothesis that the lack of IL-6 would protect against endotoxin-
induced hypoglycemia.  We based this hypothesis on previously published literature that 
indicated elevated levels of IL-6 were in part responsible for the exacerbated 
inflammatory response observed in high dose endotoxemia or sepsis (45,93).  Our data 
indicate that the absence of IL-6 is protective against LPS induced hypoglycemia.  We 
have concluded that the elevation in IL-6 is indirectly responsible for the late stage 
hypoglycemia associated with endotoxemia.    
Most studies assessing metabolic changes in endotoxemia have been conducted in 
humans and rats.  Human studies have shown that endotoxemia results in a 
hypermetabolic response characterized by an increase in glucose synthesis and release 
from the liver, leading to a brief state of hyperglycemia coupled with an elevated insulin 
concentration (20,46).  Human studies have also shown that a state of insulin resistance 
develops in the presence of conditions favorable for gluconeogenesis (22).  Our studies 
 did 
nducted in rats have shown, in addition to 
n early transient hyperglycemic phase, an end stage severe hypoglycemia occurs 
primarily because of a subsequent reduction in hepatic Ra (45).  This results in part from 
e eventual impairment in the gluconeogen onal responsiveness in 
the liver (45).  In our studies, WT mice onstrate a sustained rise in Ra but did 
revealed that all groups experienced an early transient hyperglycemia, although we
ot see an early elevation in insulin.  Studies con
a
th ic capacity and horm
 did not dem
exhibit a rise in glucose clearance, the latter being the primary cause of the 
accompanying hypoglycemia.  Other studies in rats have demonstrated an early increase 
in Ra, glucose recycling, and glucose clearance and this increase was sustained 
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throughout the four hour study period (78).  Due to sample volume constraints, we were 
not able to obtain enough data during the first 180 min of the study to adequately assess 
glucose kinetics.  Thus, we were not able to determine the time course of the early 
changes in early Ra, Rd, or glucose clearance in any of our groups.  Regardless, the 
overall response we observed in WT was similar to other species, although the difference 
in the quantitative response may be dependent on the dose of LPS used. 
Although we observed typical pro-inflammatory cytokine responses in WT, we 
were a bit surprised that TNF-α and IL-1β levels did not wane during the latter portion of 
the study as previously observed by other groups (2,39,85).  A possible explanation for 
this caveat is that we injected the bolus of LPS into the jugular vein whereas the bolus of 
LPS is typically introduced intraperitoneally (1,11,15,29,43).  This route of 
administration may have activated these cytokines in a manner that makes it difficult to 
compare with previously published data.  It is also important to note that our animals 
were surgically prepared 5 – 7 days prior to the study, which may modify the animals’ 
immunological response on our study day.  However, it is unlikely that the prior stress 
can explain the differing response since prior stress diminishes the overall response but 
does not substantially alter the time course of the response. 
 
Distinguishing between paracrine and endocrine effects associated with IL-6:  KO 
mice have no IL-6 paracrine or endocrine activity whereas WT mice with intact IL-6 
production experience an increase in both paracrine and endocrine activity of IL-6 during 
exposure to LPS.  This increase is, in part, mediated through the upregulation of TNF-α  
observed during the early infection process.  As expected, our WT mice had a significant 
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increase (P<0.027) in TNF-α within the first 30 min following the LPS bolus 
accompanied with a characteristic rise in IL-6 (Fig 10).  In contrast, although KO 
experie
ion of IL-10, and a delayed 
activation of TNF-α.  The absence of IL-6 may have facilitated this early rise.  The early 
nced an increase in TNF-α as well, this increase was delayed as compared to WT.  
As expected, IL-6 levels in KO were not detectable.  Since IL-6 can amplify TNF-α 
transcription, the absence of IL-6 in KO may explain the observed delay in TNF-α 
response (14).  The anti-inflammatory cytokine IL-10 has been associated with the 
suppression or counterregulatory effects of both IL-6 and TNF-α (29,30,51) and works 
primarily to help quell the possible detrimental effects of these cytokines (30).  Our 
findings draw a parallel with previous studies in that during early endotoxemia, IL-10 
activation has a sluggish response during the time when TNF-α and subsequently IL-6 are 
first activated in WT (14).  There is speculation that the early increase in these pro-
inflammatory cytokines may actually suppress the beneficial early activation of IL-10 
(30).  Interestingly, our KO experienced an early activat
activation of IL-10 in KO may be due to the freedom of this cytokine to be upregulated in 
the absence of the counterregulatory cytokine IL-6.  This beneficial effect of IL-10 may 
be masked or quelled by the overpowering levels of IL-6 frequently observed in 
endotoxemia.  These findings correlate with previous studies conducted where anti-TNF-
α antibodies where given prior to a bolus of LPS; IL-6 and IL-1β were blunted whereas 
IL-10 had an increased early response (12). 
 rmIL-6 was infused into IL-6 knockout mice in attempt to recreate the endocrine 
effects of WT IL-6 response to endotoxin.  It was our hypothesis that the replacement of 
IL-6 in KO would restore the IL-1β, TNF-α, and IL-10 response to endotoxin.  We found 
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this not entirely to be the case, although we were successful in recreating the IL-6 profile 
observed in WT.  Infusion of IL-6 did not correct the delayed TNF-α and IL-1β response 
to endotoxin but it did delay the IL-10 response.  A possible explanation may be that 
activation of TNF-α would not resemble the WT activation until endocrine levels of IL-6 
were high enough to trigger the positive feedback response previously mentioned.  This 
can be further validated in the respect that TNF-α levels in the KO + IL-6 group closely 
mirror the levels observed in WT from 180 min until the end of the study.  The paracrine 
effect of IL-6 is important in regard to TNF-α and IL-1β and could not be recreated by 
IL-6 infusion alone.  KO + IL-6 displayed the same sluggish IL-10 response as seen with 
WT suggesting that the endocrine effects of IL-6 are an important modulator of the IL-10 
response.   
As previously mentioned, WT fasting basal glucose were 102±11 (P<0.005) 
whereas KO and KO + IL-6 both had similar fasting basal glucose levels (145±9 and 
158±6 mg/dl; respectively).  This observation was interesting to us, as recent studies 
conducted by Di Gregorio et al. (26) have concluded that glucose levels in both WT and 
KO mice after a 4 h fast were similar and both genotypes ranged just below 200 mg/dL.  
These authors also found that there were no differences in baseline glucose or levels 
during a glucose tolerance test.  This group utilized KO mice on a C57BL/6J background 
similar to ours, although the Di Gregorio studies utilized animals from Jackson 
Laboratories whereas this differed from our studies as we used a heterozygote breeding 
scheme to obtain littermates.  The conflicting fasting glucose data observed between our 
genetic differences brought about by breeding.          
studies and the Di Gregorio studies is interesting in that this may be attributed to intrinsic 
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Absence of IL-6 resulted in a more robust early hyperglycemic response to 
endotoxin and the absence of subsequent hypoglycemia.  KO and KO + IL-6 experienced 
an early transient hyperglycemic phase whereas WT experienced a less intense early 
transient hyperglycemia.  It has been previously observed that endotoxin exposure will 
induce an early transient hyperglycemic phase and this phase is present in conjunction 
with elevated insulin levels (20,54,95) and an increase in gluconeogenesis (46).  The 
early increase in glycogenolysis and gluconeogenesis is strongly correlated with an 
increas
dose endotoxemia and it has been observed that this may contribute to increased R  and 
Rd in rats, mice, and humans (16,45,93).  With this in mind, we expected to see an 
increase in Ra and Rd in WT within 60 min, or in conjunction with the increase in IL-6, 
after giving the bolus of LPS.  We did not detect an early increase in Ra following the 
bolus of endotoxin, but did see the characteristic later increase in clearance.  As already 
mentioned our study was designed to assess glucose kinetics in the later phase of 
endotoxemia; we could not take enough samples early in the study to adequately assess 
the rapid shifts in Ra and Rd.  Consequently, we were not surprised we did not detect an 
early rise in Ra.  The increase in clearance during the late phase likely explains the fall in 
glucose in WT by the end of the study.  Previous studies conducted in rats have indicated 
that a decrease in Ra and in gluconeogenesis and concomitant depletion in glycogen 
stores along with the increase in clearance is likely the cause of the hypoglycemic state 
observed in late sepsis (16,44).  Typically, in late sepsis, insulin is decreased under basal 
values while epinephrine and glucagon are increased.  Our data indicate WT experienced 
little change in insulin or glucagon by the end of the study while epinephrine increased 
e in Ra and Rd.  Likewise, elevated levels of IL-6 have been associated with high 
a
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substantially (P<0.001).  One explanation may be that our WT animals were fairly 
glycogen depleted when basal time point sampling began.  Elevated epinephrine levels 
contribute little to the correction of end stage hypoglycemic glucose values, as previous 
studies in rats have shown elevated levels of epinephrine were not protective against 
hypoglycemia (44).  An additional possibility is that the dose of endotoxin was modest 
and did not substantially impair hepatic metabolism. 
As previously mentioned, both KO and KO + IL-6 had similar fasting basal 
glucose concentrations.  Both groups experienced an early transient hyperglycemia.  We 
postulated that the infusion of IL-6 into KO animals would recapitulate the 
immunological and hormonal responses observed in WT.  KO + IL-6 displayed a glucose 
profile similar to KO throughout the entirety of the study, even though there was a 
delayed response in both TNF-α and IL-10.  This is interesting in that it suggests the 
endocrine actions of IL-6 are not enough to alter glucose metabolism.  Another 
interesting point is that both KO and KO + IL-6 displayed a decrease in clearance in the 
first 30 min of the study and KO + IL-6 had a profound increase in clearance from 180 
min until the end of the study (P<0.050).  The early decrease in clearance may have 
contributed to the euglycemia observed at the end of the study by amplifying the 
hyperglycemia during the early phase.  It is important to keep in mind that there was 
relatively no endocrine IL-6 activity in either group during the timeframe the early 
decrease in clearance was observed.  It is also interesting to note that the substantial 
increase in clearance in KO + IL-6 from 180 min to 240 min was observed in light of no 
change in insulin, glucagon, or epinephrine, whereas KO only experienced an increase in 
glucagon at this timepoint (P<0.002).   
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Quantitative reduction in the IL-6 gene alters metabolic and immunologic properties:  
To our knowledge, there have been no previous studies in which heterozygous IL-6 
knocko
be due to the early absence of increased IL-6 
ut mice have been utilized to assess metabolic or immunologic parameters.  We 
have found that HET mice have an intermediate metabolic and immunologic response to 
a challenge of endotoxin.  Even though HET mice have one copy of the IL-6 gene, it was 
clear that endocrine levels of IL-6 remained undetectable 30 min after injection of LPS.  
This is interesting in that WT mice experienced a typical rapid increase in IL-6 by this 
time.  By the 180 min sample, HET IL-6 levels were comparable to those seen in WT and 
remained elevated for the remainder of the study.  One theory is that the IL-6 protein 
concentration must increase to a maximal level within the local interstitial compartment 
where it is produced before it is able spill into the extracellular space and subsequently 
into the circulation.  Thus, paracrine mediated effects of TNF-α and IL-6 must be at its 
maximum threshold in order to facilitate adequate endocrine activity.  This would be a 
logical order of events in that WT mice have a rapid rise in IL-6 due to the presence of 
two copies of the IL-6 allele whereas HET mice only have one allele and would be more 
dependent on time to increase the transcription cascade to produce substantial enough 
levels of IL-6 in the interstitial space.  Interestingly, the TNF-α profile in HET closely 
mirrors the pattern seen in the KO in that there was a 50% blunted response to LPS 
compared to WT.  Again, this could 
endocrine activity.  IL-10 also had a sluggish response to LPS in HET.  When examining 
the cytokine profile of HET mice, it is clear that the immunological response does not 
resemble the patterns observed with WT, but rather most closely resembles KO + IL-6.  
Our findings indicate that the quantitative reduction in the IL-6 gene causes a more 
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sluggish pro-inflammatory cytokine response and does not alter the anti-inflammatory 
response as compared to WT. 
HET exhibited a dramatic early transient hyperglycemic phase and began to 
experience a reduction in arterial glucose (82.2±3.7 mg/dl) by the last sample of the 
study.  This could suggest, since KO appear to be protected against hypoglycemia, partial 
loss of IL-6 protein in HET may be of some benefit in protecting against hypoglycemia 
as well.  Ra and Rd in HET did not change throughout the study, similar to patterns 
observed in WT, although fasting glucose was substantially higher in HET than WT 
(P<0.005).  However, glucose clearance in HET had a much different pattern than WT, in 
that clearance increased significantly from 180 min until the end of the study (P<0.008).  
This increase in clearance was similar to the pattern observed in KO.  This is interesting 
in that HET mice experienced modest changes in insulin, glucagon, or epinephrine 
throughout the study and did not become hypoglycemic, whereas WT were in fact 
hypoglycemic and had elevated epinephrine levels at the end of the study.  Given that 
HET appeared to most closely resemble the intermediate responses observed with KO + 
IL-6, it is likely that the early and complete endocrine IL-6 response to endotoxin is 
necessary to facilitate the inflammatory state typically associated with sepsis.    
 The genetic manipulation of our animals may have inadvertently interfered with 
glucose absorption kinetics, thus altering the fasting glucose profile of our animals.  
Other studies suggest that IL-6 can exert metabolic effects (29,34,40,74,84).  Our data 
indicate that KO animals were likely insulin resistant after a 5 h fast.  This finding is in 
contrast to studies performed by Kim et al. (37); IL-6 infusion had no effect on basal 
metabolism and caused hepatic insulin resistance.  It can be speculated that the Kim 
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group did not observe changes in metabolism as a result of the IL-6 infusion, but rather 
metabolism was only affected when mice were challenged with insulin (37).  Moreover, 
our infusion of IL-6 did not alter the insulin, glucagon, epinephrine, or norepinephrine 
response to endotoxin.  This can be attributed to the fact that IL-6 levels used in our 
studies were physiologically correlated with levels observed in WT mice during 
endotoxemia.  A conclusion that can be drawn from this contrast in data is that in the 
setting of endotoxemia, the role of IL-6 is different from when challenged with insulin.   
  In conclusion, KO appeared to be protected against endotoxin-induced 
hypoglycemia.  This observation is made in conjunction with elevated baseline glucose in 
all mice lacking either one or both copies of the IL-6 gene.  It is possible the early 
alterations between glycemic variables and cytokines allowed for the late term protective 
effects against hypoglycemia.  This was in conjunction with the stabilization in arterial 
glucose at the end of the study.  Our data suggest end stage glucose levels observed in 
O mK ay be attributed to factors other than hormonal catabolic mediators such as 
glucagon, epinephrine, and norepinephrine. This observation, coupled with the 
previously stated glucose kinetics profile, leads us to believe that carbohydrate 
metabolism is not altered directly through the properties of the IL-6 protein, although our 
studies indicate IL-6 is partly but not entirely responsible for the metabolic and 
immunologic profile seen during high dose endotoxemia.  Likewise, the WT metabolic 
and immunologic response could not be recreated in the IL-6 replacement group.  This 
leads us to believe that metabolic and immunologic changes observed during 
endotoxemia occur indirectly through either an IL-6 mediated transcription pathway or 
through a redundant immunological signaling pathway that includes IL-6.   
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